Pharmsynthesis

Pharmsynthesis is a Russian pharmaceutical company specializing in the development and production of drugs for treatment of socially significant diseases such as tuberculosis, HIV infection, oncology, diabetes and hepatitis. The company has been on the pharmaceutical market since 1997; its plants are located in Irkutsk, Ussuriysk, Tyumen, Bratsk and St. Petersburg.
Pharmsynthesis stock price chart
-25%
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential

Pharmsynthesis balance sheet

Report period2016 2017 2018 2019 2020 Q3 21
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Pharmsynthesis cash flows

Report period2016 2017 2018 2019 2020 Q3 21 TTM
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
EPS

Pharmsynthesis multipliers

Report period2016 2017 2018 2019 2020 Q3 21 TTM
P/E
E/P
P/B
P/S
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Pharmsynthesis profitability

Report period2016 2017 2018 2019 2020 Q3 21 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Pharmsynthesis assets
Pharmsynthesis cash flows
Pharmsynthesis dividends
0%

Pharmsynthesis shares

TickerNameРазмер выпускаNominal valueISINPrice
LIFE:RMPharmsynthesis301,010,754 pcs.RUB 5RU000A0JR514RUB 5.54
Share capital structure of Pharmsynthesis
Pharmsynthesis news
08.11.2021
Pharmsintez's RAS loss for 9M 2021 was ₽44.055 million, versus a profit of ₽226.729 million in the previous year. Revenue increased 37.9% to ₽149.617 million vs. ₽108.476 million a year earlier.
17.08.2021
Pharmsintez's RAS loss for 6M 2021 was ₽41.365 million, versus a profit of ₽102.006 million in the previous year. Revenue increased 3.6 times to ₽124.155 million vs. ₽34.787 million a year earlier.
23.06.2021
Pharmsintez and LDA Capital Group have entered into an agreement that will help fund the company's projects, including those aimed at combating COVID-19. Both companies see the capital allocation not only as an investment in the company, but also as a possible partnership to advance Pharmsintez's projects in developing treatments for complex diseases. LDA Ca...
08.06.2021
Vaccines, a company owned by Pharmsintez, will begin to develop and create production of dry nutrient media for the Sputnik V vaccine and the HFB30132A monoclonal antibody against coronavirus. The company will borrow ₽2 billion from the Russian Technological Development Fund to finance the project. It is planned to be implemented by 2024.
Source: {source} pictogram tass.ru
General information
Full nameПубличное акционерное общество "Фармсинтез"
Short nameПАО "Фармсинтез"
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressРоссийская Федерация, Ленинградская область, Всеволожский район
Mailing address188663 Российская Федерация, Ленинградская область, Всеволожский район, городской поселок Кузьмоловский, станц...
CEOПрилежаев Ефим Александрович
Phone329-80-80
Websitepharmsynthez.com
Information disclosuree-disclosure.ru